Scotia Capital Inc. Lineage Cell Therapeutics, Inc. Transaction History
Scotia Capital Inc.
- $19.9 Billion
- Q2 2025
A detailed history of Scotia Capital Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Scotia Capital Inc. holds 26,750 shares of LCTX stock, worth $50,290. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,750
Previous 26,750
-0.0%
Holding current value
$50,290
Previous $12,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding LCTX
# of Institutions
137Shares Held
99.6MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$93.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...